Aromatase Inhibitor
46 drugs across 19 manufacturers|43 Generic,3 Brand
The Aromatase Inhibitor class contains 46 NDCs from 19 manufacturers (43 generic, 3 brand), at an average NADAC of $2.82 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
46
43G / 3B
Manufacturers
19
Avg $2.8247/unit
Avg 7d Change
+0.41%
Across 40 drugs with changes
7d Activity
of 46 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
19 manufacturers producing drugs in this therapeutic class(3 pricing outliers)
and 7 more manufacturers
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Breckenridge Pharmaceutical Inc. manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
Anastrozole market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Aromatase Inhibitor class?
The Aromatase Inhibitor class contains 46 NDCs from 19 manufacturers — 43 generic and 3 brand products.
What is the average price of Aromatase Inhibitor drugs?
The average NADAC for the Aromatase Inhibitor class is $2.8247 per unit across 46 NDCs.
Is generic cheaper than brand in the Aromatase Inhibitor class?
Among products priced per EA, the average generic NADAC in this class is $0.2553, versus $39.6523 for brand — brand products average about 155× the generic price.
Which manufacturers make Aromatase Inhibitor drugs?
19 manufacturers make drugs in the Aromatase Inhibitor class. Ranked by number of NDCs, the largest are Breckenridge Pharmaceutical Inc. (7), Avet Pharmaceuticals Inc. (6), Accord Healthcare Inc. (5), Aurobindo Pharma Limited (4), Chartwell RX LLC (4).
How has Aromatase Inhibitor pricing changed recently?
Over the past 7 days, 27 NDCs in this class rose and 13 fell, with a class-wide average change of +0.4%.